Skip to main content

Advertisement

SpringerLink
Log in

Yield of 24-Hour Esophageal pH and Bilitec Monitoring in Patients with Persisting Symptoms on PPI Therapy

  • Original Paper
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Current management algorithms propose pH monitoring under proton pump inhibitors (PPIs) in suspected gastroesophageal reflux disease (GERD) with insufficient treatment response, but recent observations challenge this approach because of its low yield. Aim To perform an audit of the outcomes of pH monitoring under PPI therapy in our unit, and to study the yield of additional nonacid reflux monitoring. Methods All pH monitoring studies under antireflux therapy since 1997, with or without simultaneous Bilitec® monitoring, were analyzed. Results From 1997 to 2003, 347 patients (157 men, mean age 49.4 ± 0.8 years) underwent pH studies on PPI therapy (28% half-, 67% full-, and 5% double-dose PPI) for persisting typical (53%) or atypical (75%) symptoms. In 184 patients, simultaneous Bilitec® monitoring was performed. Esophageal pH monitoring on PPI was pathological in 105 (30%) patients. Pathological pH monitoring on PPI was associated with typical reflux symptoms (64 versus 52%, P = 0.03), and a higher prevalence of persisting esophagitis (54 versus 36%, P < 0.005) and of hiatal hernia (58 versus 27%, P < 0.005). Bilitec monitoring on PPI therapy was pathological in 114 (62%) patients, of which 74 (40%) had normal pH monitoring. Adding Bilitec® increased the rate of abnormal results over pH monitoring alone, from 38% to 69% on half-dose, from 27% to 69% on full-dose, and from 0% to 38% on double-dose PPI. Conclusions The rate of abnormal pH monitoring in symptomatic GERD patients while on PPI therapy is relatively low, especially in those on double-dose PPI. Combined pH and Bilitec® monitoring significantly increased the rate of ongoing pathological reflux compared to pH alone in refractory to PPI therapy GERD patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Isolauri J, Laippala P (1995) Prevalence of symptoms suggestive of gastroesophageal reflux disease in an adult population. Ann Med 27:67–70

    Article  PubMed  CAS  Google Scholar 

  2. Spechler SJ (1992) Epidemiology and natural history of gastroesophageal reflux disease. Digestion 51(suppl 1):24–29

    Article  PubMed  Google Scholar 

  3. Dehn TCB, Sheperd HA, Colin-Jones D et al (1990) Double blind comparison of omeprazole versus cimetidine in the treatment of symptomatic erosive reflux oesophagitis, assessed endoscopically, histologically and by 24 h pH monitoring. Gut 31:509–513

    Article  PubMed  CAS  Google Scholar 

  4. Hetzel DJ, Dent J, Reed WD et al (1988) Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 95:903–912

    PubMed  CAS  Google Scholar 

  5. Sontag SJ, Hirwhowitz BI, Holt S et al (1992) Two doses of omeprazole versus placebo in symptomatic erosive esophagitis: the U.S. multicenter study. Gastroenterology 102:108–118

    Google Scholar 

  6. Klinkenberg-Knol EC, Festen HP, Jansen JB et al (1994) Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med 121:161–167

    PubMed  CAS  Google Scholar 

  7. Earnest D, Dorsch E, Jones J et al (1998) A placebo-controlled dose-ranging study of lansoprazole in the management of reflux esophagitis. Am J Gastroenterol 93:238–243

    Article  PubMed  CAS  Google Scholar 

  8. Chiba N, De Gara CJ, Wilkonson JM et al (1997) Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 112:1798–1810

    Article  PubMed  CAS  Google Scholar 

  9. Holloway RH, Dent J, Narielvala F et al (1996) Relation between oesophageal acid exposure and healing of oesophagitis with omeprazole. Gut 38:649–654

    Article  PubMed  CAS  Google Scholar 

  10. Klinkenberg-Knol EC, Meuwissen SGM (1990) Combined gastric and esophageal 24-h pH monitoring and esophageal manometry in patients with reflux disease resistant to treatment with omeprazole. Aliment Pharmacol Ther 4:485–495

    Article  PubMed  CAS  Google Scholar 

  11. Katzka DA, Paoletti V, Leite L et al (1996) Prolonged ambulatory pH monitoring in patients with persistent gastroesophageal reflux disease symptoms: testing while on therapy identifies the need for more aggressive anti-reflux therapy. Am J Gastroenterol 91:2110–2113

    PubMed  CAS  Google Scholar 

  12. Fass R, Mackel C, Sampliner RE (1994) 24-h pH monitoring in symptomatic patients without erosive esophagitis who did not respond to antireflux treatment. J Clin Gastroenterol 19:97–99

    Article  PubMed  CAS  Google Scholar 

  13. Fass R, Shapiro M, Dekel R, Sewell J (2005) Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease-where next? Aliment Pharmacol Ther 22:79–94

    Article  PubMed  CAS  Google Scholar 

  14. Leite LP, Johnston BT, Just RJ et al (1996) Persistent acid secretion during omeprazole therapy: a study of gastric acid profiles in patients demonstrating failure of omeprazole therapy. Am J Gastroenterol 9:1527–1531

    Google Scholar 

  15. DeVault KR, Castell DO (2005) Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 100:190–200

    Article  PubMed  Google Scholar 

  16. Bautista JM, Wong WM, Pulliam G, Esquivel RF, Fass R (2005) The value of ambulatory 24 hr esophageal pH monitoring in clinical practice in patients who were referred with persistent gastroesophageal reflux disease (GERD)-related symptoms while on standard dose anti-reflux medications. Dig Dis Sci 50(10):1909–1915

    Article  PubMed  Google Scholar 

  17. Charbel S, Khandwala F, Vaezi M (2005) The role of esophageal pH monitoring in symptomatic patients on PPI therapy. Am J Gastroenterol 100:283–289

    Article  PubMed  Google Scholar 

  18. Vela M, Camacho-Lobato L, Srinivasan R, et al (2001) Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole. Gastroenterology 120:1599–1606

    Article  PubMed  CAS  Google Scholar 

  19. Zerbib F, Roman S, Ropert A, des Varannes SB, Pouderoux P, Chaput U, Mion F, Vérin E, Galmiche JP, Sifrim D (2006) Esophageal pH-impedance monitoring and symptom analysis in GERD: a study in patients off and on therapy. Am J Gastroenterol 101(9):1956–1963

    Article  PubMed  Google Scholar 

  20. Mainie I, Tutuian R, Shay S, Vela M, Zhang X, Sifrim D, Castell DO (2006) Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring. Gut 55(10):1398–1402

    Article  PubMed  CAS  Google Scholar 

  21. Tack J (2006) Review article: the role of bile and pepsin in the pathophysiology and treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 24 Suppl 2:10–6

    Google Scholar 

  22. Siddiqui A, Rodriguez-Stanley S, Zubaidi S, Miner PB Jr (2005) Esophageal visceral sensitivity to bile salts in patients with functional heartburn and in healthy control subjects. Dig Dis Sci 50(1):81–85

    Google Scholar 

  23. Orlando RC, Bozymski EM (1973) Heartburn in pernicious anemia. Aconsequence of bile reflux. N Engl J Med 289:522–523

    Google Scholar 

  24. Bechi P, Paucciani F, Baldini F, et al (1993) Long-term ambulatory enterogastric reflux monitoring. Validation of a new fiberoptic technique. Dig Dis Sci 38:1297–1306

    Google Scholar 

  25. Vaezi MF, LaCamera RG, Richter JE (1994) Bilitec 2000 ambulatory duodenogastric reflux monitoring system. Studies on its validation and limitations. Am J Phys 267:G1050–1057

    Google Scholar 

  26. Stipa F, Stein HJ, Feussner H et al (1997) Assessment of non-acidic esophageal reflux: comparison between long-term reflux aspiration test and fiberoptic bilirubin monitoring. Dis Esophagus 10:24–28

    PubMed  CAS  Google Scholar 

  27. Tack J, Koek G, Demedts I, Sifrim D, Janssens J (2004) Gastroesophageal reflux disease poorly responsive to single-dose proton pump inhibitors in patients without Barrett’s esophagus: acidreflux, bile reflux, or both? Am J Gastroenterol 99:981–988

    Article  PubMed  CAS  Google Scholar 

  28. Savary M, Miller G (1977) L’oesophage. Manuel et Atlas d’Edoscopie. Verlag Gassmann, Solothurn, Switzerland

  29. Cuomo R, Koek G, Sifrim D et al (2001) Analysis of ambulatory duodeno-gastro-esophageal reflux monitoring. Dig Dis Sci 45:246–239

    Google Scholar 

  30. Tack J, Koek GH, Bisschops R et al (2003) Dietary restrictions during ambulatory monitoring of duodeno-gastro-esophageal reflux. Dig Dis Sci 48:1213–1220

    Article  PubMed  CAS  Google Scholar 

  31. Klinkenberg-Knol E, Nelis F, Dent J et al (2000) Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety and influence on gastric mucosa. Gastroenterology 118:661–669

    Article  PubMed  CAS  Google Scholar 

  32. Castell DO, Kahrilas PJ, Richter JE et al (2002) Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 97:575–583

    Article  PubMed  CAS  Google Scholar 

  33. Karhilas PJ, Lin S, Chen J et al (1999) The effect of hiatus hernia on gastro-oesophageal junction pressure. Gut 94:476–482

    Article  Google Scholar 

  34. Cameron AJ (1999) Barrett’s esophagus: prevalence and size of hiatal hernia. Am J Gastroenterol 94:2054–2059

    Article  PubMed  CAS  Google Scholar 

  35. Fiorucci S, Santucci L, Chiuchiu S et al (1992) Gastric acidity and gastroesophageal reflux patterns in patients with esophagitis. Gastroenterology 103:855–861

    PubMed  CAS  Google Scholar 

  36. Carlsson R, Dent J, Bolling-Sternevald E et al (1998) The usefulness of a structural questionnaire in the assessment of symptomatic gastroesophageal reflux disease. Scand J Gastroenterol 33:1023–1029

    Article  PubMed  CAS  Google Scholar 

  37. Bytzer P (2003) Goal of therapy and guidelines for treatment success in symptomatic gastroesophageal reflux disease patients. Am J Gastroenterol 98(suppl):S31–S39

    Article  PubMed  Google Scholar 

  38. Cool M, Poelmans J, Feenstra L, Tack J (2004) Characteristics and clinical relevance of proximal esophageal pH monitoring. Am J Gastroenterol 99:2317–2323

    Article  PubMed  Google Scholar 

  39. Champion G, Richter JE, Vaezi MF et al (1994) Duodeno-gastro-oesophageal reflux: relationship to pH and importance in Barrett’s oesophagus. Gastroenterology 107:747–754

    PubMed  CAS  Google Scholar 

  40. Marshall RE, Anggiansah A, Manifold DK et al (1998) Effect of omeprazole 20 mg twice daily on duodenogastric and gastro-oesophageal bile reflux in Barrett’s oesophagus. Gut 43:603–606

    Article  PubMed  CAS  Google Scholar 

  41. Menges M, Muller M, Zeitz M (2001) Increased acid and bile reflux in Barrett’s esophagus compared to reflux esophagitis, and effect of proton pump inhibitor therapy. Am J Gastroenterol 96:331–337

    Article  PubMed  CAS  Google Scholar 

  42. Fass R, Naliboff B, Higa L et al (1998) Differential effect of long-term esophageal acid exposure on mechanosensitivity and chemosensitivity in humans. Gastroenterology 115:1363–1373

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gastroenterology, Department of Pathophysiology, University Hospital Gasthuisberg, University of Leuven, Leuven, Belgium

    George Karamanolis, Tim Vanuytsel, Daniel Sifrim, Raf Bisschops, Joris Arts, Philip Caenepeel, Dominiek Dewulf & Jan Tack

  2. Division of Gastroenterology, Department of Internal Medicine, University Hospital Gasthuisberg, Herestraat 49, 3000, Leuven, Belgium

    Jan Tack

Authors
  1. George Karamanolis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tim Vanuytsel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Daniel Sifrim
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Raf Bisschops
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Joris Arts
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Philip Caenepeel
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Dominiek Dewulf
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jan Tack
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jan Tack.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Karamanolis, G., Vanuytsel, T., Sifrim, D. et al. Yield of 24-Hour Esophageal pH and Bilitec Monitoring in Patients with Persisting Symptoms on PPI Therapy. Dig Dis Sci 53, 2387–2393 (2008). https://doi.org/10.1007/s10620-007-0186-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-007-0186-6

Keywords

Search

Navigation